Mount Sinai researchers report largest study supporting three courses of radiation for children with deadly brain tumor
Peer-Reviewed Publication
Updates every hour. Last Updated: 3-Nov-2026 21:16 ET (4-Nov-2026 02:16 GMT/UTC)
KRAS inhibitors shrank existing NF1-related nerve tumors and prevented new tumors from forming in a mouse model that closely mirrors the human disease, according to new research led by experts at Cincinnati Children's.
Men diagnosed with nonmetastatic prostate cancer can generally expect to live for many years after their diagnosis. However, cardiovascular disease and other cancers remain important threats to their long-term health. For many survivors, this raises an important question: What can I do to live a longer, healthier life? A new study published in JAMA Network Open suggests that the type and source of dietary fat they consume may make a difference.
The study, co-led by researchers from the Research Institute of the McGill University Health Centre (The Institute) and Harvard T.H. Chan School of Public Health, included nearly 5,000 men with nonmetastatic prostate cancer and followed them for a median of 12.8 years, drawing on data collected over more than three decades. The researchers found that the type and source of fat consumed after diagnosis were associated with long-term survival. Higher saturated fat intake, as well as higher animal fat consumption (a major dietary source of saturated fat), were associated with greater all-cause mortality. These associations were driven primarily by deaths from cardiovascular disease and, to a lesser extent, other cancers—not by prostate cancer itself.
Hematopoietic loss of chromosome Y (LOY) has emerged as one of the most prevalent somatic genomic alterations in aging males, yet its biological significance extends far beyond a mere marker of aging. This comprehensive review synthesizes current understanding of LOY, from its molecular origins in mitotic chromosome mis-segregation to its far-reaching clinical implications. Advances in detection technologies, including single-cell sequencing and bulk genomic approaches, have enabled robust identification of LOY across population scales. The review examines how inherited genetic variation, environmental exposures, and aging collectively contribute to LOY pathogenesis. Large-scale genome-wide association studies have revealed compelling epidemiological links between hematopoietic LOY and cardiovascular disease, neurodegenerative conditions, immune disorders, and cancer. Mechanistically, LOY drives altered gene expression, immune dysregulation, and clonal expansion of affected hematopoietic cells. Critically, CRISPR-based mouse and cellular models have recapitulated key disease phenotypes, establishing LOY as a functionally consequential form of somatic mosaicism with profound implications for disease susceptibility and male health disparities.
A real-world study of 145 resectable NSCLC patients who achieved pathological complete response after neoadjuvant chemoimmunotherapy found no significant disease-free or overall survival benefit from adding adjuvant immunotherapy. The findings suggest that patients with a pCR may not need further postoperative treatment, though larger prospective studies are required for confirmation.